Small interfering RNA (siRNA) has been expected to be a unique pharmaceutic for the
treatment of broad-spectrum intractable diseases. However, its unfavorable properties such …

The first closed bilayer phospholipid systems, called liposomes, were described in 1965 and
soon were proposed as drug delivery systems. The pioneering work of countless liposome …

Gene and nucleic acid therapy is expected to play a major role in the next generation of
agents for cancer treatment. We have recently developed a multifunctional envelope-type …

Neuroblastoma is a pediatric solid cancer of heterogeneous clinical behavior. The unique
features of this type of cancer frequently hamper the process of determining clinical …

According to a 2020 World Health Organization report (Globocan 2020), cancer was a
leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The aim …

Disialoganglioside GD2 is a promising target for immunotherapy with expression primarily
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …

Part of the broader glycosphingolipid family, gangliosides are composed of a ceramide
bound to a sialic acid-containing glycan chain, and locate at the plasma membrane …

Technological advances in both siRNA (small interfering RNA) and whole genome
sequencing have demonstrated great potential in translating genetic information into siRNA …

Therapeutics based on small interfering RNA (siRNA) have a huge potential for the
treatment of disease but requires sophisticated delivery systems for in vivo applications …

Angiogenesis is a process of generation of de-novo blood vessels from already existing
vasculature. It has a crucial role in different physiological process including wound healing …